

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**廣州藥業股份有限公司**

**Guangzhou Pharmaceutical Company Limited**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

**ANNOUNCEMENT  
IN RELATION TO THE PROGRESS OF  
MAJOR ASSETS REORGANIZATION**

References are made to the announcements dated 27 March 2012, 18 June 2012, 24 August 2012, 17 September 2012 and 19 September 2012 respectively and the circular dated 4 September 2012 of the Company (the “**Circular**”) in relation to the Major Assets Reorganization. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The Company received CSRC’s Acceptance Notice of the Application for Administrative Permission (No. 121723)\* (《中國證監會行政許可申請受理通知書》(121723號)) from the CSRC on 15 October 2012.

CSRC has reviewed the application materials of the Major Asset Reorganization of Guangzhou Pharmaceutical Company Limited for the Administrative Permission submitted by the Company. The CSRC considered that the application materials were complete and had complied with the statutory form and decided to accept the Application for Administrative Permission for further processing.

Whether the Major Assets Reorganization will be approved by the CSRC is still uncertain. Investors are advised by the Board to pay attention to the investment risks. The Board will comply with its disclosure obligations according to the progress of the approval of the CSRC on a timely basis.

The Board of  
**Guangzhou Pharmaceutical Company Limited**

Guangzhou, the PRC, 16 October 2012

*As at the date of this announcement, the Board comprises Mr. Yang Rongming, Mr. Li Chuyuan, Ms. Cheng Ning and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.*